Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
A trip to Colombia in my 20s turned into 8 years freelancing in South America. Here's what I'd do differently. - 2Popular Film Areas: A Worldwide Manual for Film Enchantment
- 3Iran war upends aviation strategies
- 4New Gaza militia declares war on Hamas: 'Your dirty shoes are more honorable'
- 5Ancient mass grave discovered in water cistern during Tel Azekah excavations
- The 10 Most Famous Works of art Ever
- Israeli lawmakers pass bill reviving death penalty for terrorists
- Last supermoon of the year, the cold moon, seen across the U.S.: See the photos
- Disney's latest short film 'Versa' tackles a difficult subject: Pregnancy loss. It's resonating with viewers.
- How comfort foods trigger pleasure in our brains
- Home Remodel Administrations: Change Your Residing Space
- Selena Quintanilla documentary 'Selena y Los Dinos: A Family's Legacy' is coming to Netflix
- Foot fossil discovery could reshape human evolutionary history
- The Job of Attorneys: It is Important to Comprehend When Legitimate Help
